The Endocrine Society’s new scientific statement on obesity care addresses biological adaptations, body composition, and the future of long-term medication.
On September 9, 2026, the Endocrine Society published a scientific statement in the journal Endocrine Reviews. The publication, titled “Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines,” assesses current evidence surrounding modern weight-management treatments. The release coincided with the launch of the organization's new Center on Obesity. This center is an initiative intended to accelerate obesity research, improve treatment, expand access to care, and provide educational resources for society members.
Lead author Daniel J. Drucker, MD, of the Lunenfeld-Tanenbaum Research Institute and the University of Toronto, noted that modern medicines have created an unprecedented opportunity to treat obesity over the past five years. He added that many unanswered questions currently hold immediate clinical relevance. However, the statement is explicitly nonproscriptive. Rather than issuing a rigid treatment protocol, it identifies limitations in the current evidence and highlights questions that require further study.
The scientific statement closely examines the underlying pathophysiology of obesity. A central focus is the concept of defended fat mass, which explains how our physiology regulates energy balance. For decades, outdated messaging framed weight management as simply a matter of willpower. The statement provides a biological explanation for why the human body may resist maintaining a lower weight over time.
When a person loses weight, metabolic and hormonal shifts occur to protect stored energy. The body actively defends its fat mass, adjusting appetite and energy expenditure to restore the lost weight. This process highlights why achieving sustainable results involves complex biological systems rather than just behavioral choices. Clinicians are increasingly recognizing that interventions must account for this physiological resistance.
Understanding these mechanisms helps patients make better-informed decisions about their care. Acknowledging that the body defends its energy stores removes the shame often associated with stalled progress. For a deeper look at these adaptations, understanding how hormonal shifts and metabolic adaptation impact appetite can reframe the way individuals approach long-term maintenance. Medical treatments aim to address this underlying biology, but even then, patients may wonder what happens when weight-loss medications fail to stop cravings entirely.
Mainstream media coverage often reduces the success of obesity medications to a single percentage of weight lost. The statement clarifies that this intense focus on the scale is an incomplete measure of overall treatment success. Melissa Shoemaker described the paper as a companion piece to existing clinical guidance. She praised its discussion regarding the limitations of relying solely on BMI and total weight loss.
The reality of medical weight management requires a much more nuanced approach than headlines suggest. Juliana S. Simonetti pointed out that treatment responses cannot be interpreted identically across all populations. The amount and distribution of adipose tissue can vary significantly among different racial and ethnic groups. Therefore, a universal BMI threshold or single weight-loss target may fail to capture unique differences in metabolic risk across diverse populations.
Public conversations also frequently oversimplify the issue of weight regain after stopping medication. Evidence and expert commentary reported by The Guardian indicate that weight can return after some obesity medicines are discontinued. However, the exact amount and timing of this regain vary heavily by the specific medication, the study, and the individual patient. Generalizing these outcomes without specifying the underlying study duration creates unnecessary alarm. Patients need individualized care plans that outline exactly how their progress will be monitored over time.
As the medical community moves toward a broader definition of success, body composition has become a critical clinical metric. A 2026 Medscape report detailed that lean body mass represented 25% to 39% of total weight lost across cited GLP-1 trials. This data included observations from the STEP 1 semaglutide trial. However, experts caution that claims about lean-mass loss should be interpreted carefully based on measurement methods and study populations.
A closer examination of the physiology provides important context for these body composition figures. One reanalysis reduced a reported estimate of muscle loss from 39% to 30%. This adjustment was made after accounting for the fluid and tissue protein normally lost from adipose tissue during treatment. The same report noted that surgical weight-loss studies have shown a similarly broad range of fat-free-mass loss, spanning from 12% to 44%.
These comparisons suggest that GLP-1 medicines do not have a unique effect on body composition when compared with other approaches. The Endocrine Society identifies the possible effects on muscle and bone as relevant treatment considerations, but the available discussion does not establish that every patient will experience clinically important muscle loss. Patients considering medication should ask how strength, physical function, and resistance exercise fit into their care plan. Conversations with a clinician can consider metabolic health, physical function, treatment tolerability, and the patient’s longer-term goals rather than percentage weight loss alone.
The scientific statement is structured around six specific areas that will shape the future of obesity care. These focus areas include obesity pathophysiology, heterogeneity in treatment response, and setting targets beyond simple scale weight. The framework also covers the physiology of different pharmacotherapy-response phases, associated health outcomes, and long-term medication safety. This comprehensive approach underscores that the medical community views obesity as a complex condition requiring ongoing management.
To ensure transparency in these discussions, the authors provided their professional disclosures. Drucker disclosed recent speaking activity for Novo Nordisk and Eli Lilly, alongside consulting relationships with several pharmaceutical companies. Rothberg disclosed grant funding and consulting fees from Boehringer Ingelheim, among other professional relationships. Simonetti disclosed consulting relationships with Rhythm Pharmaceuticals and Eli Lilly, while Shoemaker reported no relevant disclosures.
Amy E. Rothberg stated that the new Center on Obesity is intended to harness endocrinology expertise regarding hormonal causes. The center's materials include curated research, advocacy resources, and efforts to improve access to care. These organizational goals indicate a shift away from viewing weight management as a short-term medication trend. Instead, the focus is on creating sustainable, evidence-based systems for patient support across the entire landscape of weight loss.
Shoemaker emphasized the need for clarity regarding optimal weight-loss rates, ongoing monitoring, and dose adjustments. A medication decision should always include a discussion of expected duration and what may happen if treatment is stopped. Furthermore, evaluating sex differences in obesity and metabolic risk is just one example of how care must be customized. Individualized treatment plans ensure that adjustments are made based on a patient's unique physiological responses over time.
While modern medicines have expanded treatment possibilities, several important questions remain unresolved. The scientific statement identifies the long-term safety of newer treatments, including GLP-1 medicines, as a key priority for future research. Scientists also need more robust data detailing how individuals respond to these obesity medicines over extended periods. The Endocrine Society is currently updating its clinical practice guideline on obesity medicines, with publication expected in January 2027. This forthcoming document may translate the rapidly changing evidence landscape into practical, operational guidance for clinicians designing long-term care plans.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
